Posted by Blue Matter on May 20th, 2020.
The Blue Matter Breakfast Club is an ongoing series of two-hour breakfast forums, hosted by our team in Europe. These forums are by invitation, bringing together thought leaders and executives from biopharma companies and other organizations to discuss critical business issues.
The fourth Breakfast Club meeting was a virtual event on 13th May 2020. The guest speaker was Dr. Thomas Lönngren, Strategic Advisor and Former Executive Director of the European Medicines Agency (EMA).
The title of the presentation and discussion was Strategic Impact of the Coronavirus Pandemic on Biopharma Companies: R&D, Clinical, and Regulatory. The session included an interview with Dr. Lönngren and a Q&A session with the audience.
The discussion touched on many topics, including:
- The COVID-19 pandemic’s impact on biopharma companies in the near- and long-term
- Current and future actions of key regulatory agencies
- How companies should respond to the COVID-19 pandemic
- Outlook for COVID-19 therapies and vaccine(s)
You can access a summary of the session here: Breakfast Club Meeting “Bottom Line” #4